Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Zhijie Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2047-883X; OpenAlex author ID A5100699466. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

  1. METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43018-022-00429-3↗
  2. A two-gene-based prognostic signature for pancreatic cancer. Last author DOI 10.18632/aging.103698↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shuyi Zhou · 1 shared paper, 2020 · strength 0.12
  2. Zhenkun Lou · 1 shared paper, 2022 · strength 0.10
  3. Yu Shi · 1 shared paper, 2022 · strength 0.10
  4. Kaixiong Tao · 1 shared paper, 2022 · strength 0.10
  5. Min Deng · 1 shared paper, 2022 · strength 0.10
  6. Xiangyu Zeng · 1 shared paper, 2022 · strength 0.10
  7. Xinyi Tu · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.